NCT06745687 is a NA clinical trial of CM336 in High Risk Smoldering Multiple Myeloma, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT06745687?

NCT06745687 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT06745687?

Interventions in NCT06745687: CM336.

What condition does NCT06745687 study?

NCT06745687 studies High Risk Smoldering Multiple Myeloma.

Is NCT06745687 still recruiting?

NCT06745687 is currently not yet recruiting. Last updated 20 December 2024.

Last reviewed 2024-12-20 · How we verify

NCT06745687

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

Not yet recruiting NA Last updated 20 December 2024

What this trial tests

NA trial testing CM336 in High Risk Smoldering Multiple Myeloma in 20 participants. Not yet recruiting.

Timeline

30 December 2024

Primary endpoint
1 August 2026

1 August 2028

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	30 December 2024
Primary completion	1 August 2026
Estimated completion	1 August 2028
Sites	1 location across China

Drugs / interventions tested

CM336

Conditions studied

High Risk Smoldering Multiple Myeloma — all drugs for High Risk Smoldering Multiple Myeloma →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

Adults 18 to 78, any sex, with High Risk Smoldering Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of CM-336, which is a BCMA/CD3 BiTE, in the treatment of high risk smoldering multiple myeloma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for High Risk Smoldering Multiple Myeloma

Currently open trials in the same condition.

NCT06574126 — Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma · Phase 2 · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06745687 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 20 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06745687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing